Prospects for a group a streptococcal vaccine: Rationale, feasibility, and obstacles - Report of a national institute of allergy and infectious diseases workshop
Prospects for a group a streptococcal vaccine: Rationale, feasibility, and obstacles - Report of a national institute of allergy and infectious diseases workshop
复制标题
DOI：
10.1086/444505
复制
发表时间：
2005-10-15
影响因子：
11.8
通讯作者：
Dale, JB
中科院分区：
文献类型：
--
作者：
Bisno, AL;Rubin, FA;Dale, JB
A组链球菌感染在发展中国家和发达国家都是一个重要的公共卫生问题。目前可用的预防方法要么不充分，要么无效，这一点可以从世界各地与这种普遍存在的病原体相关的发病率和死亡率中得到证明。分子生物学的进展为GAS感染的发病机制提供了新的线索，并确定了许多毒力因子作为潜在的疫苗靶点。因此，国家过敏和传染病研究所于2004年3月召开了一次专家研讨会，审查现有数据，并探讨安全有效的GAS疫苗的开发和实施所涉及的微生物学、免疫学、流行病学和经济问题。与会者包括参与GAS研究的科学家和临床医生，以及美国联邦机构（疾病控制和预防中心、食品和药物管理局、国防部和国家过敏和传染病研究所）、世界卫生组织和制药行业的代表。本报告概述了研讨会的讨论情况。
Infections due to group A streptococci (GAS) represent a public health problem of major proportions in both developing and developed countries. Currently available methods of prevention are either inadequate or ineffective, as attested to by the morbidity and mortality associated with this ubiquitous pathogen worldwide. Advances in molecular biology have shed new light on the pathogenesis of GAS infections and have identified a number of virulence factors as potential vaccine targets. Therefore, the National Institute of Allergy and Infectious Diseases convened an expert workshop in March 2004 to review the available data and to explore the microbiologic, immunologic, epidemiologic, and economic issues involved in development and implementation of a safe and effective GAS vaccine. Participants included scientists and clinicians involved in GAS research, as well as representatives of United States federal agencies (Centers for Disease Control and Prevention, Food and Drug Administration, Department of Defense, and National Institute of Allergy and Infectious Diseases), the World Health Organization, and the pharmaceutical industry. This report summarizes the deliberations of the workshop.